연구동향 분석
박사

Characterization of lipoprotein properties and functions by aging stress, oxidation, and glycation = 노화 스트레스 (산화, 당화) 에 의한 혈청 지단백질의 기능 및 성상 변화 연구

박기훈 2015년

논문상세정보
인용/피인용
' Characterization of lipoprotein properties and functions by aging stress, oxidation, and glycation = 노화 스트레스 (산화, 당화) 에 의한 혈청 지단백질의 기능 및 성상 변화 연구' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • aging stress
  • glycation
  • high-density lipoprotein
  • oxidation
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
188 0

0.0%

' Characterization of lipoprotein properties and functions by aging stress, oxidation, and glycation = 노화 스트레스 (산화, 당화) 에 의한 혈청 지단백질의 기능 및 성상 변화 연구' 의 참고문헌

  • van der Westhuyzen DR, de Beer FC, and Webb NR. (2007) HDL cholesterol transport during inflammation. Curr. Opin. Lipidol., 18:147?151.
  • van Sickle WA, Wilcox HG, Malik KU, and Nasjletti A. (1986) High density lipoprotein induced cardiac prostacyclin synthesis in vitro: relationship to cardiac arachidonate mobilization. J. Lipid Res., 27:517-522.
  • Yuhanna IS, Zhu Y, Cox BE, Hahner LD, Osborne-Lawrence S, Lu P, Marcel YL, Anderson RG, Mendelsohn ME, Hobbs HH, and Shaul PW. (2001) Highdensity lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase. Nat. Med., 7:853-857.
  • Yoshikawa M, Sakuma N, Hibino T, Sato T, and Fujinami T. (1997) HDL3 exerts more powerful anti-oxidative, protective effects against copper-catalyzed LDL oxidation than HDL2. Clin. Biochem., 30:221-225.
  • Yoon JH and Cho KH. (2012) A point mutant of apolipoprotein A-I (V156K) showed enhancement of cellular insulin secretion and potent activity of facultative regeneration in zebrafish. Rejuvenation Res., 15:313-321.
  • Wu FCW and von Eckardstein A. (2003) Androgens and coronary artery disease. Endocrine Reviews, 24:183?217.
  • Wilson PWF, Anderson KM, Harris T, Kannel WB, and Castelli WP. (1994) Determinants of change in total cholesterol and HDLC with age: the Framingham study. J. Gerontol., 49:M252?M257.
  • Wilson PW. (1990) High-density lipoprotein, low density lipoprotein and coronary artery disease. Am. J. Cardiol., 66:7A-10A.
  • Wallance RB and Colsher PL. (1992) Blood lipids distribution in older persons: prevalence and correlates of hyperlipidemia. Ann. Epidemiol., 2:15-21.
  • Wadham C, Albanese N, Roberts J, Wang L, Bagley CJ, Gamble JR, Rye KA, Barter PJ, Vadas MA, and Xia P. (2004) High density lipoproteins neutralize C-reactive protein proinflammatory activity. Circulation, 109:2116-2122
  • Uhlar CM and Whitehead AS. (1999) Serum amyloid A, the major vertebrate acutephase reactant. Eur. J .Biochem., 265:501-523.
  • Udenfriend S, Stein S, Bohlen P, Dairman W, Leimgruber W, and Weigele M. (1972) Fluorescamine: a reagent for assay of amino acids, peptides, proteins, and primary amines in the picomole range. Science, 178:871-872.
  • Tselepis AD, Tsoumani ME, Kalantzi KI, Dimitriou AA, Tellis CC, and Goudevenos IA. (2011) Influence of HDL and paraoxonase-1 on platelet reactivity in patients with acute coronary syndromes receiving clopidogrel therapy. J. Thromb. Haemost., 9:2371-2378.
  • Trede NS, Zapata A, and Zon L. (2001) Fishing for lymphoid genes. Trends Immunol., 22:302-307.
  • Tan KC, Chow WS, Ai VH, Mets C, Bucala R, and Lam KS. (2002) Advanced glycation end products and endothelial dysfunction in type 2 diabetes. Diabetes Care, 25:1055-1059.
  • Stein O and Stein Y. (1999) Atheroprotective mechanisms of HDL. Atherosclerosis, 144:285-301.
  • Staros JV. (1982) N-hydroxysulfosuccinimide active esters: bis(Nhydroxysulfosuccinimide) esters of two dicarboxylic acids are hydrophilic, membrane-impermeant, protein crosslinkers. Biochemistry, 21:3950-3955.
  • Spieker LE, Sudano I, Hurlimann D, Lerch PG, Lang MG, Binggeli C, Corti R, Ruschitzka F. L scher TF, and Noll G. (2002) High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation, 105:1399-1402.
  • Smith RE, and MacQuarrie R. (1978) A sensitive fluorometric method for the determination of arginine using 9,10-phenanthrenequinone. Anal. Biochem., 90:246-255.
  • Silva RA, Hilliard GM, Li L, Segrest JP, and Davidson WS. (2005) A mass spectrometric determination of the conformation of dimeric apolipoprotein A-I in discoidal high density lipoproteins. Biochemistry, 44:8600-8607.
  • Seres I, Paragh G, Deschene E, Fulop T, and Khalil A. (2004) Study of factors influencing the decreased HDL associated PON1 activity with aging. Exp. Greontol., 39:59-66.
  • Segrest JP, Harvey SC, and Zannis V. (2000) Detailed molecular model of apolipoprotein A-I on the surface of high-density lipoproteins and its functional implications. Trends Cardiovasc. Med., 10:246-252.
  • Schalkwijk CG, Stehouwer CD, and van Hinsbergh VW. (2004) Fructosemediated non-enzymatic glycation: sweet coupling or bad modification. Diabetes Metab. Res. Rev., 20:369-382.
  • Scarmeas N. (2007) Invited commentary: lipoproteins and dementia-is it the apolipoprotein A-I?. Am. J. Epidemiol., 165:993-997.
  • Rye KA, Hime NJ, and Barter PJ. (1994) Evidence that choesteryl ester transfer protein-mediated reductions in reconstituted high-density lipoprotein size involve particle fusion. J. Biol. Chem., 272:3953-3960.
  • Rye KA and Barter PJ. (2004) Formation and metabolism of prebeta-migrating, lipid-poor apolipoprotein A-I. Arterioscler. Thromb. Vasc. Biol., 24:421-428.
  • Rutti S, Ehses JA, Sibler RA, Prazak R, Rohrer L, Georgopoulos S, Meier DT, Niclauss N, Berney T, Donath MY, and von Eckardstein A. (2009) Low- and high-density lipoproteins modulate function, apoptosis, and proliferation of primary human and murine pancreatic beta-cells. Endocrinology, 150:4521- 4530.
  • Rutledge AC and Adeli K. (2007) Fructose and the metabolic syndrome: patophysiology and molecular mechanisms. Nutr. Rev., 65:S13-S23.
  • Rohrer L, Hersberger M, and von Eckardstein A. (2004) High density lipoproteins in the intersection of diabetes mellitus, inflammation and cardiovascular disease. Curr. Opin. Lipidol., 15:269-278.
  • Pu DR and Liu L. (2008) HDL slowing down endothelial progenitor cells senescence: a novel anti-atherogenic property of HDL. Med. Hypotheses, 70:338-342.
  • Pownall HJ, Massey JB, Kusserow SK, and Gotto AM Jr. (1978) Kinetics of lipid-protein interactions: interaction of apolipoprotein A-I from human plasma high density lipoproteins with phosphatidylcholines. Biochemistry, 17:1183-1188.
  • Posin G, Gotto AM Jr, Utermann G, and Pownall HJ. (1985) Abnormal interaction of the human apolipoprotein A-I variant [Lys107->0] with high density lipoproteins. Biochem. Biophys. Res. Commun., 133:856-862.
  • Pongor S, Ulrich PC, Bencsath FA, and Cerami A. (1984) Aging of proteins: isolation and identification of a fluorescent chromophore from the reaction of polypeptides with glucose. Proc. Natl. Acad. Sci. U. S. A., 81:2684-2688.
  • Podrez EA. (2010) Anti-oxidant properties of high-density lipoprotein and atherosclerosis. Clin. Exp. Pharmacol. Physiol., 37:719?725.
  • Peterson SJ, Kim DH., Li M, Positano V, Vanella L, Rodella LF, Piccolomini F, Puri N, Castaldelli A, Kusmic C, L’Abbate A, and Abraham NG. (2009) The L-4F mimetic peptide prevents insulin resistance through increased levels of HO-1, pAMPK, and pAKT in obese mice. J. Lipid Res., 50:1293-1304 .
  • Park KH, Shin DG, and Cho KH. (2014b) Dysfunctional lipoproteins from young smokers exacerbate cellular senescence and atherogenesis with smaller particle size and severe oxidation and glycation. Toxicol. Sci., 140:16-25.
  • Park KH, Shin DG, Kim JR, and Cho KH. (2010b) Senescence-related truncation and multimerization of apolipoprotein A-I in high-density lipoprotein with an elevated level of advanced glycated end products and choesteryl ester transfer activity. J. Gerontol. A Biol. Sci .Med. Sci., 65:600-610.
  • Park KH, Kim JM, and Cho KH. (2014a) Elaidic acid (EA) generates dysfunctional high-density lipoproteins and consumption of EA exacerbates hyperlipidemia and fatty liver change in zebrafish. Mol. Nutr. Food Res., 58:1537-1545.
  • Park KH, Jang W, Kim KY, Kim JR, and Cho KH. (2010a) Fructated apolipoprotein A-I showed severe structural modification and loss of beneficial functions in lipid-free and lipid-bound state with acceleration of atherosclerosis and senescence. Biochem. Biophys. Res. Commun., 392:295? 300.
  • Park KH and Cho KH. (2011b) High-density lipoprotein (HDL) from elderly and reconstituted HDL containing glycated apolipoproteins A-I share proatherosclerotic and prosenescent properties with increased cholesterol influx. J. Gerontol. A Biol. Sci .Med. Sci., 66:511-520.
  • Park KH and Cho KH. (2011a) A zebrafish model for the rapid evaluation of prooxidative and inflammatory death by lipopolysaccharide, oxidized lowdensity lipoproteins, and glycated high-density lipoproteins. Fish Shellfish Immunol., 31:904-910.
  • Panzenb ck U, Kritharides L, Raftery M, Rye KA, and Stocker R. (2000) Oxidation of methionine residues to methionine sulfoxides does not decrease potential antiatherogenic properties of apolipoprotein A-I. J. Biol. Chem., 275:19536-19544.
  • Owusu-Ansah E, Yavari A, Mandal S, and Banerjee U. (2008) Distinct mitochondrial retrograde signals control the G1-S cell cycle checkpoint. Nat. Genet., 40:356-361..
  • Oslakovic C, Krisinger MJ, Andersson A, Jauhiainen M, Ehnholm C, and Dahlback B. (2009) Anionic phospholipids lose their procoagulant properties when incorporated into high density lipoproteins. J. Biol. Chem., 284:5896- 5904.
  • Nusslein-Volhard C and Dahm R. (2002) Zebrafish: a practical approach. Oxford University Press.
  • Novoa B, Bowman TV, Zon L, and Figueras A. (2009) LPS response and tolerance in the zebrafish (Danio rerio). Fish Shellfish Immunol., 26:326-331.
  • Nofer JR, Walter M, and Assmann G. (2005) Current understanding of the role of high-density lipoproteins in atherosclerosis, senescence. Expert Rev. Cardiovasc. Ther., 3:1071-1086.
  • Nofer JR, Kehrel B, Fobker M, Levkau B, Assmann G, and von Eckardstein A. (2002) HDL and arteriosclerosis: beyond reverse cholesterol transport. Atherosclerosis, 161:1-16.
  • Nofer JR, Brodde MF, and Kehrel BE. (2010) High-density lipoproteins, platelets and the pathogenesis of atherosclerosis. Clin. Exp. Pharmacol. Physiol., 37:726-735.
  • Nobecourt E, Jacqueminet S, Hansel B, Chantepie S, Grimaldi A, Chapman MJ, and Kontush A. (2005) Defective antioxidative activity of small, dense HDL particles in type 2 diabetes: relationship to elevated oxidative stress and hyperglycemia. Diabetologia, 48:529-538.
  • Nobecourt E, Davies MJ, Brown BE, Curtiss LK, Bonnet DJ, Charlton F, Januszewski AS, Jenkins AJ, Barter PJ, and Rye KA. (2007) The impact of glycation on apolipoprotein A-I structure and its ability to activate lecithin:cholesterol acyltransferase. Diabetologia, 50:643-653.
  • Navab M, Hama SY, Hough GP, Subbanagounder G, Reddy ST, and Fogelman AM. (2001) A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids. J. Lipid Res., 42:1308-1317.
  • Navab M, Hama SY, Anantharamaiah GM, Hassan K, Hough GP, Watson AD, Reddy ST, Sevanian A, Fonarow GC, and Fogelman AM. (2000) Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3. J. Lipid Res., 41:1495-1508.
  • Nakagawa T, Hu L, Zharikov S, Tuttle KR, Short RA, Glushakova O, Ouyang X, Feig DI, Block ER, Herrera-Acosta J, Patel JM, and Johnson RJ. (2006) A causal role for uric acid in fructose-induced metabolic syndrome. Am. J. Physiol. Renal. Physiol., 290:F625-F631.
  • Morgantini C, Natali A, Boldrini B, Imaizumi S, Navab M, Fogelman AM, Ferrannini E, and Reddy ST. (2011) Anti-inflammatory and antioxidant properties of HDLs are impaired in type 2 diabetes. Diabetes, 60:2617-2623.
  • Miyazaki A, Nakayama H, and Horiuchi S. (2002) Scavenger receptors that recognize advanced glycation end products. Trends Cardiovasc. Med., 12:258-262.
  • Minamino T, Miyauchi H, Yoshida T, Ishida Y, Toshida H, and Komuro I. (2002) Endothelial cell senescence in human atherosclerosis: role of telomere in endothelial dysfunction. Circulation, 105:1541-1544.
  • Mikhailidis DP, Elisaf M, Rizzo M, Berneis K, Griffin B, Zambon A, Athyros V, de Graaf J, M rz W, Parhofer KG, Rini GB, Spinas GA, Tomkin GH, Tselepis AD, Wierzbicki AS, Winkler K, Florentin M, and Liberopoulos E. (2011) ‘‘European panel on low density lipoprotein (LDL) subclasses’’: a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. Curr. Vasc. Pharmacol., 9:533-571.
  • Markwell MA, Haas SM, Bieber LL, and Tolbert NE. (1978) A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. Anal. Biochem., 87:206?210.
  • Maiorano JN, Jandacek RJ, Horace EM, and Davidson WS. (2004) Identification and structural ramifications of a hinge domain in apolipoprotein A-I discoidal highdensity lipoproteins of different size. Biochemistry, 43:11717-11726.
  • Liang H, Rye KA, and Barter PJ. (1994) Dissociation of lipid-free apolipoproteinA-I from high-density lipoprotein. J. Lipid Res., 35:1187-1199.
  • Lagos KG, Filippatos TD, Tsimihodimos V, Gazi IF, Rizos C, Tselepis AD, Mikhailidis DP, and Elisaf MS. (2009) Alterations in the high density lipoprotein phenotype and HDL-associated enzymes in subjects with metabolic syndrome. Lipids, 44:9-16.
  • L KA and Tappy L. (2006) Metabolic effects of fructose. Curr. Opin. Clin. Nutr. Metab. Care, 9:469-475.
  • Kreisberg RA and Kasim S. (1987) Cholesterol metabolism and aging. Am. J. Med., 82:54-60.
  • Kontush A. (2004) Apolipoprotein Aβ: black sheep in a good family. Brain Pathol., 14: 433-447.
  • Kontush A, Chantepie S, and Chapman MJ. (2003) Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress. Arterioscler. Thromb. Vasc. Biol., 23:1881-1888.
  • Kontush A and Chapman MJ. (2006) Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol. Rev., 58:342-374.
  • Knott HM, Brown BE, Davies MJ, and Dean RT. (2003) Glycation and glycoxidation of low-density lipoproteins by glucose and low-molecular mass aldehydes. Eur. J. Biochem., 270: 3572-3582.
  • Khovidhunkit W, Kim MS, Memon RA, Shigenaga JK, Moser AH, Feingold KR, and Grunfeld C. (2004) Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J. Lipid Res., 45:1169-1196.
  • Khalil A, Jay-Gerin JP, and Fulop T. (1998) Age-related increased susceptibility of high-density lipoproteins (HDL) to in vitro oxidation induced by γ- radiolysis of water. FEBS. Lett., 435:153-158.
  • Kastelein JJ, van Leuven SI, Burgess L, Evans GW, Kuivenhoven JA, Barter PJ, Revkin JH, Grobbee DE, Riley WA, Shear CL, Duggan WT, Bots ML, and RADIANCE 1 investigators. (2007) Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N. Engl. J. Med., 356:1620- 1630.
  • Jonas A. (2000) Lecithin cholesterol acyltransferase. Biochim. Biophys. Acta, 1529, 245-256.
  • Jang W, Shim J, Lee DY, Dutta P, Kim JR, and Cho KH. (2011) Rapid detection of dysfunctional high-density lipoproteins using isoelectric focusing-based microfluidic device to diagnose senescence-related disease. Electrophoresis, 32:3415-3423.
  • Hoang A, Murphy AJ, Coughlan MT, Thomas MC, Forbes JM, O’Brien R, Cooper ME, Chin-Dusting JP, and Sciridov D. (2007) Advanced glycation of apolipoprotein A-I impaires its anti-atherogenic properties. Diabetologia, 50:1770-1779.
  • Hedrick CC, Thorpe SR, Fu MX, Harper CM, Yoo J, Kim SM, Wong H, and Peters AL. (2000) Glycation impaires high-density lipoprotein function. Diabetologia, 43:312-320.
  • Havel PJ. (2005) Dietary fructose: implications for dysregulation of energy homeostasis and lipid/carbohydrate metabolism. Nutr. Rev., 63:133-157.
  • Hansel B, Giral P, Nobercourt E, Chantepie S, Bruckert E, Chapman MJ, and Kontush A. (2004) Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity. J. Clin. Endocrinol. Metab., 89:4963-4971.
  • Han JM, Jeong TS, Lee WS, Choi I, and Cho KH. (2005) Structural and functional properties of V156K and A158E mutants of apolipoprotein A-I in the lipid-free and lipid-bound states. J. Lipid Res., 46:589-596.
  • Grossin N and Wautier JL. (2007) Protein glycation and endothelium dysfunction. J. Soc. Biol., 201:175-184.
  • Goulinet S and Chapman MJ. (1997) Plasma LDL and HDL subspecies are heterogenous in particle content of tocopherols and oxygenated and hydrocarbon carotenoids: relevance to oxidative resistance and atherogenesis. Arterioscler. Thromb. Vasc. Biol., 17:786-796.
  • Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, Jacobs DR Jr, Bangdiwala S, and Tyroler HA. (1989) High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation, 79:8-15.
  • Gordon DJ and Rifkind BM. (1989) High-density lipoproteins-the clinical implications of recent studies. N. Engl. J. Med., 321:1311-1316.
  • Galle J, Hansen-Hagge T, Wanner C, and Seibold S. (2006) Impact of oxidized low density lipoprotein on vascular cells. Atherosclerosis, 185:219-226.
  • Fryirs MA, Barter PJ, Appavoo M, Tuch BE, Tabet F, Heather AK, and Rye KA. (2010) Effects of high-density lipoproteins on pancreatic beta-cell insulin secretion. Arterioscler. Thromb. Vasc. Biol., 30:1642-1648.
  • Frank PG and Marcel YL. (2000) Apolipoprotein A-I: structure-function relationship. J. Lipid Res., 41:853-872.
  • Florentin M, Liberopoulos EN, Wierzbicki AS, and Mikhailidis DP. (2008) Multiple actions of high-density lipoprotein. Curr. Opin. Cardiol., 23:370- 378.
  • Ferretti G, Bacchetti T, Negre-Salvayre A, Salvayre R, Dousset N, and Curatola G. (2006) Structural modifications of HDL and functional consequences. Atherosclerosis, 184:1-7.
  • Ferrara A, Barrett-Connor E, and Shan J. (1997) Total, LDL, and HDL cholesterol decrease with age in older men and women The Rancho Bernardo Study 1984?1994. Circulation, 96:37-43.
  • Esterbauer H, Striegl G, Puhl H, and Rotheneder M. (1989) Continuous monitoring of in vitro oxidation of human low density lipoprotein. Free Radic. Res. Commun., 6:67-75.
  • Erlich PM, Lunetta KL, Cupples LA, Huyck M, Green RC, Baldwin CT, Farrer LA, and MIRAGE Study Group. (2006) Polymorphisms in the PON gene cluster are associated with Alzheimer disease. Hum. Mol. Genet., 15:77-85.
  • Eckerson HW, Wyte CM, and La Du BN. (1983) The human serum paraoxonase/arylesterase polymorphism. Am. J. Hum. Genet., 35:1126?1138.
  • Eberini I, Gianazza E, Breghi L, Klugmann S, Calabresi L, Gomaraschi M, Mombelli G, Brusoni B, Wait R, and Sirtori CR. (2007) Apolipoprotein A-I breakdown is induced by thrombolysis in coronary patients. Ann. Med., 39:306-311.
  • Eberini I, Calabresi L, Wait R, Tedeschi G, Pirillo A, Puglisi L, Sirtori CR, and Gianazza E. (2002) Macrophage metalloproteinases degrade high-density lipoprotein A-I at both the N- and C-termini. Biochem. J., 362:627-634.
  • Drew BG, Duffy SJ, Formosa MF, Natoli AK, Henstridge DC, Penfold SA, Thonas WG, Mukhamedova N, de Courten B, Forbes JM, Yap FY, Kaye DM, van Hall G, Febbraio MA, Kemp BE, Sviridov D, Steinberg GR, and Kingwell BA. (2009) High-density lipoprotein modulates glucose metabolism in patients with type 2 diabetes mellitus. Circulation, 119:2103- 2111 .
  • Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, Medrano EE, Linskens M, Rubelj I, Pereira-smith O, Peacocke M, and Campisi J. (1995) A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl. Acad. Sci. U. S. A., 92:9363-9367.
  • Clifton PM, Mackinnon AM, and Barter PJ. (1985) Effects of serum amyloid A protein (SAA) on composition, size, and density of high density lipoproteins in subjects with myocardial infarction. J. Lipid Res., 26:1389-1398.
  • Clay MA, Newnham HH, Forte TM, and Barter PI. (1992) Cholesteryl ester transfer protein and hepatic lipase activity promote shedding of apo A-I from HDL and subsequent formation of discoidal HDL. Biochim. Biophys. Acta, 1124:52-58.
  • Cho KH. (2011) Enhanced delivery of rapamycin by V156K-apoA-I high-density lipoprotein inhibits cellular proatherogenic effects and senescence and promotes tissue regeneration. J. Gerontol. A Biol. Sci. Med. Sci., 66:1274- 1285.
  • Cho KH. (2009b) Synthesis of reconstituted high-density lipoprotein (rHDL) containing apoA-I and apoC-III: the functional role of apoC-III in rHDL. Mol. Cells, 27:291-297.
  • Cho KH. (2009a) Biomedicinal implications of high-density lipoproteins: its composition, structure, functions, and clinical applications. BMB. Rep., 42:393-400.
  • Cho KH, Shin DG, Baek SH, and Kim JR. (2009c) Myocardial infarction patients showed altered lipoprotein compositions compared with angina pectoris patients. Exp. Mol. Med., 41:67-76.
  • Cho KH, Park SH, Park JE, Kim YO, Choi I, Kim JJ, and Kim JR. (2008) The function, composition, and particle size of high-density lipoprotein were severely impaired in an oliguric phase of hemorrhagic fever with renal syndrome patients. Clin. Biochem., 41:56-64.
  • Cho KH, Park SH, Han JM, Kim HC, Choi YK, and Choi I. (2006) ApoA-I mutants V156K and R173C promote anti-inflammatory function and antioxidant activities, Eur. J. Clin. Invest., 27:291-297.
  • Cho KH, Lee JY, Choi MS, Cho JM, Lim JS, and Park YB. (1998) A peptide from hog plasma that inhibits human cholesteryl ester transfer protein. Biochim. Biophys. Acta, 1391:133-144.
  • Chapman MJ, Goldstein S, Lagrange D, and Laplaud PM. (1981) A density gradient ultracentrifugal procedure for the isolation of the major lipoprotein classes from human serum. J. Lipid Res., 22:339-358.
  • Castelli WP. (1988) Cholesterol and lipids in the risk of coronary artery disease. The Framingham heart study. Can. J. Cardiol., 4 (Suppl. A):5A-10A.
  • Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, and Kannel WB. (1986) Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham study. J. Am. Med. Assoc., 256:2835-2838.
  • Calvo C, Talussot C, Ponsin G, and Berthezene F. (1988) Non enzymatic glycation of apolipoprotein A-I. Effects on its self-association and lipid binding properties. Biochem. Biophys. Res. Commun., 153:1060-1067.
  • Brown BE, Nobecourt E, Zeng J, Jenkins AJ, and Rye KA. (2013) Apolipoprotein A-I glycation by glucose and reactive aldehydes alters phospholipid affinity but not cholesterol export from lipid-laden macrophages. PLoS One, 8:e65430.
  • Brinton EA. (1996) Oral estrogen replacement therapy in postmenopausal women selectively raises levels and production rates of lipoprotein AI and lowers hepatic lipase activity without lowering the fractional catabolic rate. Arterioscler. Thromb. Vasc. Biol., 16:431-440.
  • Brewer HB Jr, Ronan R, Meng M, and Bishop C. (1986) Isolation and characterization of apolipoprotein A-I, A-II, and A-IV. Meth. Enzymol., 28:223-246.
  • Boulanger E, Puisieux F, Gaxatte C, and Wautier JL. (2007) Aging: role and control of glycation. Rev. Med. Interne., 28:832-840.
  • Borownlee M, Cerami A, and Vlassara H. (1988) Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N. Engl. J. Med., 318:1315-1321.
  • Bisoendial RJ, Hovingh GK, Levels JH, Lerch PG, Andresen I, Hayden MR, Kastelein JJ, and Stroes ES. (2003) Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein. Circulation, 107:2944-2948.
  • Berrougui H, Isabelle M, Cloutier M, Grenier G, and Khalil A. (2007) Agerelated impairment of HDL-mediated cholesterol efflux. J. Lipid Res., 48:328?336.
  • Benzie IF and Strain JJ. (1996) The ferric reducing ability of plasma (FRAP) as a measure of antioxidant power: the FRAP assay. Anal. Biochem., 239:70-76.
  • Barzilai N, Atzmon G, Schechter C, Schaefer EJ, Cupples AL, Lipton R, Cheng S, and Shuldiner AR. (2003) Unique lipoprotein phenotype and genotype associated with exceptional longevity. J. Am. Med. Assoc., 290:2030-2040.
  • Barter PJ, Nichollas S, Rye KA, Anantharamaiah GM, Navab M, and Fogelman AM. (2004) Antiinflammatory properties of HDL. Circ. Res., 95:764-772.
  • Barter P. (2004) HDL: a recipe for longevity. Atheroscler. Suppl., 5:25-31.
  • Barter P, Kastelein J, Nunn A, and Hobbs R. (2003) High density lipoproteins (HDLs) and atherosclerosis; the unanswered questions. Atherosclerosis, 168:195-211.
  • Bantle JP. (2009) Dietary fructose and metabolic syndrome and diabetes. J. Nutr., 139:1263S-1268S.
  • Baggio G, Donazzan S, Monti D, Mari D, Martini S, Gabelli C, Dalla Vestra M, Previato L, Guido M, Pigozzo S, Cortella I, Crepaldi G, and Franceschi C. (1998) Lipoprotein (a) and lipoprotein profile in healthy centenarians: a reappraisal of vascular risk factors. FASEB. J., 12:433-437.
  • Ayub A, Mackness MI, Arrol S, Mackness B, Patel J, and Durrington PN. (1999) Serum paraoxonase after myocardial infarction. Arterioscler. Thromb. Vasc. Biol., 19:330-335.
  • Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, and La Du BN. (1998) Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. J. Clin. Invest., 101:1581-1590.
  • Asztalos BF and Schaefer EJ. (2003) HDL in atherosclerosis: actor or bystander? Atheroscler. Suppl., 4:21-29.
  • Anderson DW, Nichols AV, Forte TM, and Lindgren FT. (1977) Particle distribution of human serum high density lipoproteins. Biochim. Biophys. Acta, 493:55-68.
  • ?Agrawal A, Hammond DJ, and Singh SK. (2010) Atherosclerosis-related functions of C reactive protein. Cardiovasc. Hematol. Disord. Drug Targets, 10:235-240.